Generated by AI
Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s work centers on antibody-drug conjugates and other oncology-focused modalities designed to identify and attack specific disease targets while limiting effects on healthy tissue. Its current portfolio includes late-stage and early-stage programs such as varegacestat for desmoid tumors, IM-1021, and additional investigational assets in radiotherapy and solid-tumor antibody-drug conjugates. Immunome also uses proprietary antibody discovery capabilities to support the identification of novel therapeutic candidates and targets. Based in Bothell, Washington, Immunome operates as a research-driven drug development company serving the oncology market through a pipeline of clinical and preclinical assets.
Website18702 North Creek Parkway
Bothell, WA, 98011
United States
The latest articles about IMNM.
Summary of Aug 10's posts. Generated by AI.
Summary of Dec 19's posts. Generated by AI.
Summary of Aug 10's posts. Generated by AI.
Investors talking about IMNM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.